News
BCRX
6.42
+4.73%
0.29
Weekly Report: what happened at BCRX last week (0513-0517)?
Weekly Report · 1d ago
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) fell sharply after the company reported first-quarter financial results. AERWINS Technologies Inc. Shares surged 201% to $ on Wednesday. Sintx Technologies jumped 169% after jumping over 41% on Tuesday.
Benzinga · 6d ago
Wednesday Sector Leaders: General Contractors & Builders, Biotechnology Stocks
NASDAQ · 6d ago
BioCryst Pharmaceuticals Form 4 Filings Shows CCO Charles K Gayer Bought 30,000 Shares At An Average Price Of $5.47/Share; CEO Jon P Stonehouse Bought 30,000 Shares At An Average Price Of $5.55/Share; Steven K Galson Bought 21,940 Shares At An Average Price Of $5.49/Share; Helen M. Thackray Bought 30,000 Shares At An Average Price Of $5.86/Share; Anthony Doyle Bought 36,300 Shares At An Average Price Of $5.57/Share
Benzinga · 6d ago
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
Shares of Nextracker Inc. Rose sharply after the company reported better-than-expected fourth-quarter financial results. The Dow Jones gained around 150 points on Wednesday. Other big stocks recording gains include BioCryst Pharmaceuticals, Inc. And B&G Foods.
Benzinga · 6d ago
BioCryst spikes after a series of insider purchases
Shares of BioCryst Pharmaceuticals, Inc. (BCRX) spiked after a series of insider purchases. The CEO and CFO of the North Carolina-based biotech company bought a total of 30K shares on Monday and Tuesday. The company's stock is trading sharply higher on Wednesday.
Seeking Alpha · 6d ago
Biocryst Pharmaceuticals, T2 Biosystems, Annovis Bio among healthcare movers
Healthcare On the Move Biocryst Pharmaceuticals, T2 Biosystems, Annovis Bio among healthcare movers. S&P 500 Health Care Sector contributes 58% to index. SINTX Technologies, Virpax Pharmaceuticals among the biggest losers.
Seeking Alpha · 6d ago
OPEN, BCRX and AWIN among pre-market gainers
Seeking Alpha · 6d ago
ORLADEYO® (BEROTRALSTAT) APPROVED IN MEXICO
Reuters · 05/13 11:08
Weekly Report: what happened at BCRX last week (0506-0510)?
Weekly Report · 05/13 09:03
BioCryst Pharmaceuticals, Inc. Quarterly Report: Financial Results and Business Updates
Press release · 05/08 00:24
BioCryst Pharmaceuticals Price Target Raised to $15.00/Share From $14.00 by JMP Securities
Dow Jones · 05/07 15:39
BioCryst Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Dow Jones · 05/07 15:39
JMP Securities Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $15
Benzinga · 05/07 15:29
January 2026 Options Now Available For BioCryst Pharmaceuticals (BCRX)
NASDAQ · 05/07 14:37
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), BioCryst (BCRX) and Syndax Pharmaceuticals (SNDX)
TipRanks · 05/07 12:21
BioCryst (BCRX) Receives a Buy from RBC Capital
TipRanks · 05/07 12:06
Buy Rating for BioCryst’s Orladeyo: Poised for Pediatric Market Growth and Continued HAE Market Penetration
TipRanks · 05/07 11:49
BioCryst Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Dow Jones · 05/07 10:27
BioCryst: Estimate-Beating Q1 But Risks Are Considerable
Seeking Alpha · 05/07 10:15
More
Webull provides a variety of real-time BCRX stock news. You can receive the latest news about Biocryst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.